Kodiak Sciences Inc. (KOD)

Market Cap	303.98M
Revenue (ttm)	n/a
Net Income (ttm)	-191.62M
Shares Out	52.50M
EPS (ttm)	-3.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	337,616
Open	5.65
Previous Close	5.64
Day's Range	5.60 - 5.92
52-Week Range	2.19 - 7.77
Beta	2.25
Analysts	Hold
Price Target	3.50 (-39.55%)
Earnings Date	Nov 26, 2024

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative dia...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: KOD
• Website: https://kodiak.com

Analyst Forecast

According to 5 analysts, the average rating for KOD stock is "Hold." The 12-month stock price forecast is $3.5, which is a decrease of -39.55% from the latest price.

Price Target

$3.5

(-39.55% downside)

Analyst Consensus: Hold